Inovio Pharmaceuticals Receives 'Buy' Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
Sphere Entertainment Analyst Ratings
Selective Insurance Gr Analyst Ratings
Varonis Systems Analyst Ratings
Alkami Technology Analyst Ratings
Alarm.com Holdings Analyst Ratings
Palomar Hldgs Analyst Ratings
JPMorgan Raises Price Target on Fidelis Insurance to $20 From $18.50, Maintains Neutral Rating
Buy Rating Affirmed for PROCEPT BioRobotics Amid Strong Reimbursement Prospects for Aquablation Therapy
Goosehead Insurance Analyst Ratings
InMode Analyst Ratings
Fidelis Insurance Hldgs Analyst Ratings
The Baldwin Insurance Analyst Ratings
IDEAYA Biosciences Analyst Ratings
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $61
Remitly Global Analyst Ratings
Goldman Sachs Maintains Sell on Manitowoc Co, Lowers Price Target to $13
E2open Parent Holdings Analyst Ratings
BofA Securities Trims Price Target on Selective Insurance to $97 From $98, Maintains Underperform Rating
Bank of N.T Butterfield Analyst Ratings